Notable Price Action: What Will Happen to Affimed NV Next? The Stock Just Reaches All-Time Low

Notable Price Action: What Will Happen to Affimed NV Next? The Stock Just Reaches All Time Low

The stock of Affimed NV (NASDAQ:AFMD) reached all time low today, Oct, 17 and still has $1.98 target or 11.00% below today’s $2.23 share price. This indicates more downside for the $71.20M company. This technical setup was reported by Barchart.com. If the $1.98 PT is reached, the company will be worth $7.83 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 65,799 shares traded hands. Affimed NV (NASDAQ:AFMD) has declined 42.08% since March 14, 2016 and is downtrending. It has underperformed by 47.69% the S&P500.

Analysts await Affimed NV (NASDAQ:AFMD) to report earnings on November, 8. They expect $-0.25 earnings per share, up 7.41% or $0.02 from last year’s $-0.27 per share. After $-0.27 actual earnings per share reported by Affimed NV for the previous quarter, Wall Street now forecasts -7.41% EPS growth.

Affimed NV (NASDAQ:AFMD) Ratings Coverage

Out of 7 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. Affimed Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was downgraded by Leerink Swann to “Market Perform” on Thursday, May 19. Zacks upgraded the shares of AFMD in a report on Monday, August 10 to “Sell” rating. As per Thursday, December 10, the company rating was initiated by Laidlaw. The stock of Affimed NV (NASDAQ:AFMD) earned “Outperform” rating by BMO Capital Markets on Tuesday, April 12. The stock of Affimed NV (NASDAQ:AFMD) earned “Market Perform” rating by Leerink Swann on Friday, August 12. The firm has “Hold” rating by Jefferies given on Wednesday, September 9. The firm has “Outperform” rating given on Thursday, August 6 by Oppenheimer. The firm earned “Hold” rating on Thursday, May 19 by Jefferies. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. The firm earned “Hold” rating on Thursday, September 3 by Zacks.

According to Zacks Investment Research, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany.”

More news for Affimed NV (NASDAQ:AFMD) were recently published by: Quotes.Wsj.com, which released: “Affimed NV AFMD (US: Nasdaq)” on September 05, 2014. Zacks.com‘s article titled: “Should You Get Rid of Affimed N.V. (AFMD) Now?” and published on August 14, 2015 is yet another important article.

AFMD Company Profile

Affimed N.V., incorporated on May 1, 2014, is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. The Company’s research and development pipeline consists of AFM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. The Firm generates its pipeline of product candidates from three platform technologies based on its tetravalent antibody architecture characterized by four binding domains, creating bispecific NK-cell and T-cell TandAbs (binding to two different targets) and Trispecific Abs (binding to three different targets). The Company’s bispecific antibodies, TandAbs, are designed to direct and establish a bridge between either Natural Killer (NK)-cells or T-cells and cancer cells. The Company’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment